62 related articles for article (PubMed ID: 12229869)
1. Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease.
Rafael H
Neurosurgery; 2002 Sep; 51(3):852-3. PubMed ID: 12229869
[No Abstract] [Full Text] [Related]
2. Citicoline is not protective in experimental models of Huntington's disease.
Mievis S; Levivier M; Vassart G; Brotchi J; Ledent C; Blum D
Neurobiol Aging; 2007 Dec; 28(12):1944-6. PubMed ID: 17064815
[TBL] [Abstract][Full Text] [Related]
3. The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases.
Steele AD; Jackson WS; King OD; Lindquist S
Proc Natl Acad Sci U S A; 2007 Feb; 104(6):1983-8. PubMed ID: 17261803
[TBL] [Abstract][Full Text] [Related]
4. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
[TBL] [Abstract][Full Text] [Related]
5. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease.
Nguyen HP; Kobbe P; Rahne H; Wörpel T; Jäger B; Stephan M; Pabst R; Holzmann C; Riess O; Korr H; Kántor O; Petrasch-Parwez E; Wetzel R; Osmand A; von Hörsten S
Hum Mol Genet; 2006 Nov; 15(21):3177-94. PubMed ID: 16984963
[TBL] [Abstract][Full Text] [Related]
6. Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats.
Dhir A; Akula KK; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):835-43. PubMed ID: 18234412
[TBL] [Abstract][Full Text] [Related]
7. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
8. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease.
Pang TY; Du X; Zajac MS; Howard ML; Hannan AJ
Hum Mol Genet; 2009 Feb; 18(4):753-66. PubMed ID: 19008301
[TBL] [Abstract][Full Text] [Related]
9. Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease.
van Dellen A; Grote HE; Hannan AJ
Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1007-19. PubMed ID: 16445565
[TBL] [Abstract][Full Text] [Related]
10. Animal models of Huntington's disease.
Gárdián G
Ideggyogy Sz; 2006 Nov; 59(11-12):396-9. PubMed ID: 17203874
[TBL] [Abstract][Full Text] [Related]
11. The role of the striatum in rule application: the model of Huntington's disease at early stage.
Teichmann M; Dupoux E; Kouider S; Brugières P; Boissé MF; Baudic S; Cesaro P; Peschanski M; Bachoud-Lévi AC
Brain; 2005 May; 128(Pt 5):1155-67. PubMed ID: 15788544
[TBL] [Abstract][Full Text] [Related]
12. [Juvenile onset Huntington's disease: correlation with progressive myoclonus epilepsy].
Sato K; Abe K
Ryoikibetsu Shokogun Shirizu; 2002; (37 Pt 6):198-200. PubMed ID: 12483860
[No Abstract] [Full Text] [Related]
13. Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats.
Kántor O; Temel Y; Holzmann C; Raber K; Nguyen HP; Cao C; Türkoglu HO; Rutten BP; Visser-Vandewalle V; Steinbusch HW; Blokland A; Korr H; Riess O; von Hörsten S; Schmitz C
Neurobiol Dis; 2006 Jun; 22(3):538-47. PubMed ID: 16480885
[TBL] [Abstract][Full Text] [Related]
14. [Experimental models of Huntington's disease].
García-Ramos R; del Val-Fernández J; Catalán-Alonso MJ; Barcia-Albacar JA; Matías-Guiu J
Rev Neurol; 2007 Oct 1-15; 45(7):437-41. PubMed ID: 17918112
[TBL] [Abstract][Full Text] [Related]
15. Huntington's disease, behavioral disturbances, and kynurenines: preclinical findings and therapeutic perspectives.
Vécsei L; Beal MF
Biol Psychiatry; 1996 Jun; 39(12):1061-3. PubMed ID: 8780845
[No Abstract] [Full Text] [Related]
16. Fly models of Huntington's disease.
Marsh JL; Pallos J; Thompson LM
Hum Mol Genet; 2003 Oct; 12 Spec No 2():R187-93. PubMed ID: 12925571
[TBL] [Abstract][Full Text] [Related]
17. Neural correlates associated with impaired disgust processing in pre-symptomatic Huntington's disease.
Hennenlotter A; Schroeder U; Erhard P; Haslinger B; Stahl R; Weindl A; von Einsiedel HG; Lange KW; Ceballos-Baumann AO
Brain; 2004 Jun; 127(Pt 6):1446-53. PubMed ID: 15090475
[TBL] [Abstract][Full Text] [Related]
18. Neurotrophic enhancers as therapy for behavioral deficits in rodent models of Huntington's disease: use of gangliosides, substituted pyrimidines, and mesenchymal stem cells.
Dunbar GL; Sandstrom MI; Rossignol J; Lescaudron L
Behav Cogn Neurosci Rev; 2006 Jun; 5(2):63-79. PubMed ID: 16801683
[TBL] [Abstract][Full Text] [Related]
19. Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus.
Ayalon L; Doron R; Weiner I; Joel D
Exp Neurol; 2004 Mar; 186(1):46-58. PubMed ID: 14980809
[TBL] [Abstract][Full Text] [Related]
20. Living with Huntington's disease: need for supportive care.
Dawson S; Kristjanson LJ; Toye CM; Flett P
Nurs Health Sci; 2004 Jun; 6(2):123-30. PubMed ID: 15130098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
